quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:00:00·38d
PRRelease
Gyre Therapeutics Inc. logo

Gyre Therapeutics Announces China's NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment

GYRE· Gyre Therapeutics Inc.
Health Care
Original source

Companies

  • GYRE
    Gyre Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Oct 10UpdateJefferies$16.00
  • Aug 26UpdateH.C. Wainwright$18.00
  • Mar 11UpdateNoble Capital Markets-

Related

  • SEC7d
    Amendment: Gyre Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
  • SEC7d
    SEC Form PRE 14A filed by Gyre Therapeutics Inc.
  • SEC32d
    Gyre Therapeutics Inc. filed SEC Form 8-K: Other Events
  • SEC41d
    SEC Form 10-K filed by Gyre Therapeutics Inc.
  • SEC43d
    Gyre Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure
  • SEC43d
    Gyre Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • PR43d
    Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
  • SEC53d
    Gyre Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Unregistered Sales of Equity Securities, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022